National Academies Press: OpenBook
« Previous: Front Matter
Suggested Citation:"1 Introduction." Institute of Medicine. 2011. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press. doi: 10.17226/13038.
×

1
Introduction

Biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to an intervention. Cholesterol and blood sugar levels are biomarkers, as are blood pressure, enzyme levels, measurements of tumor size from magnetic resonance imaging (MRI) or computed tomography (CT), and the biochemical and genetic variations observed in age-related macular degeneration. Biomarkers can enable faster, more efficient clinical trials for life-saving and health-promoting interventions. They can help improve understanding of healthy dietary choices, and they can help public health professionals to identify and track health concerns. Biomarkers help health care practitioners and their patients make decisions about patient care. (IOM, 2010)

Due to the absence of an agreed-upon process for biomarker evaluation, the Food and Drug Administration (FDA) requested that the Institute of Medicine (IOM) recommend a framework for the evaluation of biomarkers in the chronic disease setting and make ancillary recommendations for its application. In a report published in May 2010, the IOM Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease (henceforth, “the committee”) recommended such a framework, comprising three critical components: analytical validity, evidentiary qualification, and utilization analysis (IOM, 2010). This framework is intended to bring consistency and transparency to the previously nonuniform process of biomarker evaluation. The full summary of the committee’s report is included in Appendix B.

On June 21 and 22, 2010, the IOM convened a 2-day discussion forum in Washington, DC, in order to provide an opportunity for stakeholders to learn about, react to, and discuss the report, Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (IOM, 2010; see Appendix A). The discussion forum was attended by representatives of several FDA centers, including the Center for Food Safety and Applied Nutrition (CFSAN), the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Devices and Radiological Health (CDRH); by representatives of the National Institutes of Health (NIH), including the National Heart, Lung, and Blood Institute (NHLBI) and the Office of Dietary Supplements; by representatives of industry and industrial professional societies, including food, dietary

Suggested Citation:"1 Introduction." Institute of Medicine. 2011. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press. doi: 10.17226/13038.
×

supplements, pharmaceuticals, medical diagnostics, and devices; and by representatives of public health, consumer, and nutrition consulting organizations, as well as by members of the committee and IOM staff.

Presentations reviewed the committee’s work process, recommendations, and provided perspectives on the report from the point of view of participants from the FDA, the NIH, and from a diverse group of industry stakeholders; all such sessions were followed by panel discussions. Many presenters emphasized that the views they expressed were theirs and not necessarily those of their organizations or institutions. Thomas Fleming, professor of biostatistics and statistics at the University of Washington, gave a keynote presentation on the critical issues in the validation of surrogate endpoints, a specific use of a biomarker.

This document recounts the discussion forum proceedings, focusing in turn on each represented sector. A summary of Dr. Fleming’s presentation then sets the committee’s report within the context of biomarker utilization. Lastly, this summary examines the main themes raised by stakeholders, and the challenges and opportunities presented to stakeholders by the report’s recommendations.

Suggested Citation:"1 Introduction." Institute of Medicine. 2011. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press. doi: 10.17226/13038.
×
Page 1
Suggested Citation:"1 Introduction." Institute of Medicine. 2011. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press. doi: 10.17226/13038.
×
Page 2
Next: 2 Committee Findings and Recommendations »
Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary Get This Book
×
Buy Paperback | $46.00 Buy Ebook | $36.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

In 2010 the Institute of Medicine (IOM) recommended a framework for the evaluation of biomarkers in the chronic disease setting. Published in the book Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease, the framework is intended to bring consistency and transparency to the previously disparate process of biomarker evaluation.

Following the book's release, the IOM convened a 2-day discussion forum in Washington, DC, in order to provide an opportunity for stakeholders to learn about, react to, and discuss the book. Presentations reviewed the authoring committee's work process, recommendations, and provided perspectives on the book from the point of view of participants. Thomas Fleming, professor of biostatistics and statistics at the University of Washington, gave a keynote presentation on the critical issues in the validation of surrogate endpoints, a specific use of a biomarker.

The present volume recounts the discussion forum proceedings, focusing in turn on each represented sector. A summary of Dr. Fleming's presentation then sets the committee's recommendations within the context of biomarker utilization. Lastly, this summary examines the main themes raised by stakeholders, and the challenges and opportunities presented to stakeholders by the book's recommendations.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!